NEWRON PHARMACEUTICALS SPA
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000QXX403
NWRN
NEWRON PHARMACEUTICALS SPA
GICS: -
·
Sector: EQTY
·
Sub-Sector: -
NAME
NEWRON PHARMACEUTICALS SPA
ISIN
IT0004147952
TICKER
NWRN
MIC
XSWX
REUTERS
NWRN.MI
BLOOMBERG
NWRN SW
F&G:
71
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 12.05.2025
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the approval for its pivotal ENIGMA-TRS Phase III development program evaluating evenamide as an add-on therapy to curre...
Newron Pharmaceuticals
Tue, 01.04.2025
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2024, and provided an outlook ...
Newron Pharmaceuticals
Tue, 11.03.2025
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 a.m. PDT.
...
Newron Pharmaceuticals
Thu, 09.01.2025
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, and Myung In Pharm Co. Ltd. (“Myung In Pharm”), South Korea’s leading CNS specialist pharmaceutical company, today announced that they have entered in...
Newron Pharmaceuticals
Fri, 13.12.2024
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and EA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”), a subsidiary of Eisai Co., Ltd., ...
Newron Pharmaceuticals
Thu, 19.09.2024
Newron Pharmaceuticals
IT0004147952
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended June 30, 2024, and provided an update on its bu...
Newron Pharmaceuticals
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
